Elizabeth Nieto-Mendoza

Dr. Elizabeth Nieto-Mendoza


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2018 in Brain Sciences
Verified
Journal Article
Open access
PDF file
JFJorge Flores-Hernandez
Jorge Flores-Hernandez
JGJeanette A. Garzón-Vázquez
Jeanette A. Garzón-Vázquez
GHGustavo Hernández-Carballo
Gustavo Hernández-Carballo
ENElizabeth Nieto-Mendoza
Elizabeth Nieto-Mendoza
EREvelyn A. Ruiz-Luna
Evelyn A. Ruiz-Luna
EHElizabeth Hernández-Echeagaray
Elizabeth Hernández-Echeagaray
Huntington’s Disease (HD) is a degenerative disease which produces cognitive and motor disturbances. Treatment with GABAergic agonists improves the behavior and activity of mitochondrial complexes in rodents treated with 3-nitropropionic acid to mimic HD symptomatology. Apparently, GABA receptors activity may protect striatal medium spiny neurons (MSNs) from excitotoxic damage. This study evaluates whether mitochondrial inhibition with 3-NP that mimics the early stages of HD, modifies the kinetics and pharmacology of GABA receptors in patch clamp recorded dissociated MSNs cells. The results show that MSNs from mice treated with 3-NP exhibited differences in GABA-induced dose-response currents and pharmacological responses that suggests the presence of GABAC receptors in MSNs. Furthermore, there was a reduction in the effect of the GABAC antagonist that demonstrates a lessening of this GABA receptor subtype activity as a result of mitochondria inhibition.